Rendu Biotech (688193.SH): Cumulative repurchase of 1.00% of the company's shares

Gelonghui, April 11, 丨 Rendu Biotech (688193.SH) announced that as of April 10, 2024, the company had repurchased 400,049 shares of the company's shares through centralized bidding transactions, accounting for 1.00% of the company's total share capital of 40,000,000 shares, an increase of 0.02% compared with the previous disclosure. The highest price of the repurchase transaction was 30.00 yuan/share, and the lowest price was 28.47 yuan/share. The total amount of capital paid was RMB 11,938,945.00 (excluding stamp duty and transactions) transaction costs such as commissions).

Gelonghui FinanceApr 11 17:10

Rendu Biotech (688193.SH): Accumulated repurchases of 392,200 shares

Gelonghui, April 1, 丨 Rendu Biotech (688193.SH) announced that as of March 31, 2024, the company had repurchased 392,167 shares of the company's shares through centralized bidding transactions, accounting for 0.98% of the company's total share capital. The highest price of the repurchase transaction was 30.00 yuan/share, the lowest price was 28.47 yuan/share, and the total capital paid was RMB 11,702,640.53 (excluding transaction fees such as stamp duty and transaction fees).

Gelonghui FinanceApr 1 16:32

Rendu Biotech (688193.SH): The ban on 500,000 restricted shares was lifted on April 1

Gelonghui March 20 丨 Rendu Biotech (688193.SH) announced that the total number of shares in circulation in the company's current stock listing is 500,000 shares. The stock listing and circulation date is April 1, 2024 (postponed to the next trading day since March 30, 2024 is a non-trading day).

Gelonghui FinanceMar 20 17:32

Rendu Biotech (688193.SH): A total of 202,300 shares have been repurchased as of February 29

Gelonghui, March 1, 丨 Rendu Biotech (688193.SH) announced that as of February 29, 2024, the company had repurchased a total of 202,341 shares of the company's shares through centralized bidding transactions, accounting for 0.5059% of the company's total share capital. The highest price of the repurchase transaction was 30.00 yuan/share, the lowest price was 28.47 yuan/share, and the total capital paid was RMB 6,027,229.31 (excluding transaction fees such as stamp duty and transaction fees).

Gelonghui FinanceMar 1 16:07

Rendu Biotech (688193.SH) performance report: 2023 net profit of 3.182,200 yuan, a year-on-year decrease of 86.36%

On February 27, Ge Longhui Biotech (688193.SH) announced the 2023 Annual Results Report. During the reporting period, the company achieved operating income of 165 million yuan, a year-on-year decrease of 45.86%, and realized net profit attributable to owners of the parent company of 3.182,200 yuan, a year-on-year decrease of 86.36%; realized net profit attributable to the owner of the parent company after deducting non-recurring gains and losses of 125.903 million yuan, a year-on-year decrease of 354.89%.

Gelonghui FinanceFeb 27 17:59

Rendu Biotech (688193.SH): Initial repurchase of 26,500 shares

On February 22, 2024, Gelonghui Biotech (688193.SH) announced that on February 22, 2024, the company repurchased 26,463 shares of the company's shares for the first time through centralized bidding transactions, accounting for 0.0662% of the company's total share capital. The highest price of the repurchase transaction was 30.00 yuan/share, the lowest price was 29.28 yuan/share, and the total capital commission paid was RMB 790,345.29 (excluding transaction fees such as stamp duty and transaction fees).

Gelonghui FinanceFeb 22 16:16